Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

Study Identifier:
CLI-05993AB6-03
ClinicalTrials.gov Identifier:
NCT06264674
EudraCT Identifier:
N/A
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Asthma
Study Drug
  • Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a
  • Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a
Date
Nov 2023 - Nov 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Healthy Volunteers
No

Protocol Summary

The CLI-05993AB6-03 Study is an interventional study designed to investigate the safety and efficacy of a new low global warming potential propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma

Study Locations

Location
Status
Location
Yerevan State Medical University, Heratsi N 1 University Hospital Complex
Yerevan, Armenia, 0025
Status
N/A
Location
CITO Medical Center
Yerevan, Armenia, 0070
Status
N/A
Location
Armenia Republican Medical Center
Yerevan, Armenia, 0078
Status
N/A
Location
Erebuni Medical Center
Yerevan, Armenia, 0087
Status
N/A
Location
Nairi Medical Center
Yerevan, Armenia, 0087
Status
N/A
Location
"IPSMCPP-D-R Veleva" EOOD
Burgas, Bulgaria
Status
N/A